As expected, blockade of HMGB1 remarkably reduced diabetes incidence (84.6% vs 60%) (Fig. 1d) and delayed diabetes onset (16.7 ± 0.8 vs 19.6 ± 1.1 weeks) (Fig. 1e). Here, HMGB1 is linked to diabetes mellitus.